Tetra Therapeutics focuses on developing drugs that target PDE4B and PDE4D to improve memory loss and cognitive impairment in diseases such as Alzheimer's Disease. They also offer consulting services in drug discovery and development, partnering with universities to commercialize intellectual property and conduct research on diseases affecting the central nervous system, with a particular focus on developing new treatments for depression and schizophrenia.